Article Text

PDF
Vitreous relapse following primary chemotherapy for retinoblastoma: is adjuvant diode laser a risk factor?
  1. D S Gombos1,2,5,
  2. P A Cauchi1,
  3. J L Hungerford1,2,
  4. P Addison1,
  5. P G Coen4,
  6. J E Kingston1,3
  1. 1Ocular Oncology Service, Bart’s and The London NHS Trust, London, UK
  2. 2Ocular Oncology Service, Moorfields Eye Hospital, London, UK
  3. 3Paediatric Oncology Service, Bart’s and The London NHS Trust, London, UK
  4. 4Academic Department of Child Health, Queen Mary, University of London, UK
  5. 5Section of Ophthalmology, Department of Head and Neck Surgery, MD Anderson Cancer Center, Houston, TX, USA
  1. Correspondence to: MrJohn L Hungerford FRCS, Department of Ophthalmology, Ocular Oncology Service, St Bartholomew’s Hospital, West Smithfield, London EC1A 7BE, UK; paulcauchi{at}doctors.org.uk

Abstract

Aims: To evaluate rates of vitreous relapse among retinoblastoma patients treated with primary chemotherapy and assess diode laser as a potential risk factor for relapse.

Methods: Retrospective review of all patients treated with primary chemotherapy at a large ocular oncology centre. Eyes that developed vitreous relapse were coded with regard to Reese-Ellsworth Group, laterality, time to relapse, type of relapse (vitreous base or non-vitreous base relapse), treatments used (including adjuvant diode laser), and ocular preservation. Individual tumour foci treated with laser hyperthermia were also coded for laser parameters including power settings, number of treatments, and concomitant administration of systemic chemotherapy (chemothermotherapy).

Results: 15 of 106 eyes (14.15%) developed vitreous relapse over a 6 year period. Mean time to relapse was 7.2 months after chemotherapy was completed. Five cases (33%) were of the vitreous base variety. Ocular salvage was attempted in 11 cases using a variety of methods; one patient was lost to follow up. Six of the remaining 10 eyes (60%) were salvaged. Eight of 38 eyes (21%) treated with systemic chemotherapy and laser hyperthermia developed vitreous relapse compared with seven of 68 eyes (10%) treated with primary chemotherapy alone (p<0.005). Laser settings, number of hyperthermia treatments, and the concomitant use of systemic chemotherapy (chemothermotherapy) were not associated with higher rates of vitreous relapse.

Conclusion: Nearly one in seven eyes with retinoblastoma treated with primary chemotherapy may develop vitreous relapse. The administration of diode laser hyperthermia appears to increase this risk. Despite additional therapy a number of these eyes succumb to enucleation.

  • EBRT, external beam radiotherapy
  • ILM, internal limiting membrane
  • TTT, transpupillary thermotherapy
  • retinoblastoma
  • chemotherapy
  • vitreous relapse
  • laser hyperthermia
  • transpupillary thermotherapy
  • children
  • EBRT, external beam radiotherapy
  • ILM, internal limiting membrane
  • TTT, transpupillary thermotherapy
  • retinoblastoma
  • chemotherapy
  • vitreous relapse
  • laser hyperthermia
  • transpupillary thermotherapy
  • children

Statistics from Altmetric.com

Footnotes

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.